SBRT Boost for Prostate Cancer

Recruiting in Palo Alto (17 mi)

Overseen byAriel E. Hirsch

Age: 18+

Sex: Male

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: Boston Medical Center

No Placebo Group

Trial Summary

What is the purpose of this trial?

In this study, participants will have standard Androgen Deprivation Therapy and undergo standard external beam radiation therapy to the prostate and at-risk lymph nodes by Intensity Modulated Radiation Therapy. The subsequent \*boost\* radiation therapy to the prostate alone will be given using the CyberKnife, rather than using the standard Intensity Modulated Radiation Therapy. This study will also see how CyberKnife affects the quality of the participant's life.

Research Team

Ariel E. Hirsch

Principal Investigator

Boston Medical Center

Eligibility Criteria

This trial is for men over 18 with prostate cancer, a Gleason score of 2-10, and no prior pelvic radiotherapy or prostate surgery. They must be able to have an MRI, not have inflammatory bowel disease or certain other health conditions, and agree to complete questionnaires.

Inclusion Criteria

My prostate cancer is classified as high risk based on PSA levels, Gleason score, or tumor stage.

I am undergoing or planning to start hormone therapy and radiation for prostate cancer.

My prostate is larger than 20cc but smaller than 100cc.

See 15 more

Exclusion Criteria

I haven't had chemotherapy for cancer in the last 5 years.

No implanted hardware (including metal) or other material that would prohibit appropriate treatment planning or treatment delivery

I haven't had any cancer except for skin cancer in the last 5 years.

See 8 more

Treatment Details

Interventions

CyberKnife Boost (Radiation Therapy)

Trial OverviewThe study tests if using CyberKnife for boost radiation therapy after standard treatments improves outcomes in prostate cancer patients. It compares this method against the usual Intensity Modulated Radiation Therapy boost while monitoring quality of life impacts.

Participant Groups

1Treatment groups

Experimental Treatment

Group I: BoostExperimental Treatment1 Intervention

CyberKnife Boost 21 Gy in 7 Gy per day, 3 fractions, Every other day